
    
      This is a Single center, single dose, open label, randomized, two-way, crossover, food effect
      on bioavailability study.

      More precisely, a single oral dose of 400 mg of ladarixin (two 200 mg capsules) was
      administered to healthy male and female volunteers under fed (Test treatment) and fasting
      (Reference treatment) conditions in two consecutive study periods, according to a two-way
      crossover design, with a wash-out interval of at least 14 days between the two
      administrations.
    
  